Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
Active, not recruiting · NCT02259621 · Registry updated 2026-09-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-09-10 | NCT02259621 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 117 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Johnathan Spicer | Montreal | Canada | 1 |
| Johns Hopkins at Bayview Medical Center | Baltimore | United States | 1 |
| Memorial Sloan Kettering | New York | United States | 27 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | United States | 24 |
| Swedish Cancer Insitute | Edmonds | United States | 1 |